PTC Therapeutics Inc.
(NASDAQ:PTCT) on Wednesday said it is expanding its rare disease portfolio through the planned acquisition of the ST-920 Fabry disease program from Sangamo Therapeutics in a competitive bankruptcy auction.
The move comes during a mixed market session, with S&P 500 futures showing a gain of 0.5%. • PTC Therapeutics stock is holding steady today.
What's next for PTCT stock?
PTC Therapeutics Expands Fabry Disease Pipeline With ST-920 Deal The terms include $111 million upfront and up to $100 million in contingent milestone payments based on certain regulatory approvals.
